Biomaterial-based strategies to prime dendritic cell-mediated anti-cancer immune responses. (2nd October 2020)

• Record Type: Journal Article
• Authors: Park, Wooram; Song, Kwang Hoon; Lim, Jaesung; Park, Chun Gwon; Doh, Junsang; Han, Dong Keun
• Is Part Of: International materials reviews. Volume 65:Number 7(2020)
• Page Start: 445
• Page End: 462
• Publication Date: 2020-10-02
• Subjects: Cancer immunotherapy -- biomaterials -- multifunctional nanoparticles -- biocompatible scaffolds -- priming anti-cancer immune responses; Materials science -- Periodicals; Chemistry, Physical and theoretical -- Periodicals; Chemical engineering -- Periodicals; Metallurgy -- Periodicals; 620.1105
• DOI: 10.1080/09506608.2020.1735117
• Languages: English
• ISSNs: 0950-6608

Abstract

ABSTRACT: Cancer immunotherapy has been extremely successful in curing patients over the last decade. Immune checkpoint blockades (ICBs) that unleash the brakes in T-cells to promote cytotoxicity against cancer cells are the most successful forms of cancer immunotherapy, yet therapeutic efficacy needs to be improved as only a fraction of patients responds. Dendritic cells (DCs) are immune cells that prime immune responses by collecting information in tumour tissues, and carrying that information to T-cells, thus delivering proper information to DCs is essential. Biomaterial-based approaches can be powerful tools for this purpose, as biomaterials allow us to deliver a variety of immunotherapeutic agents at the right time and place. Herein, we review the key concepts of cancer immunotherapy; discuss the principles for designing biomaterials to deliver immunomodulatory molecules; and outline biomaterial-based strategies to prime anti-cancer immune responses. Specifically, we focus on two widely used forms of biomaterials, multifunctional nanoparticles and biocompatible scaffolds.